PAS-003 / Pasithea - LARVOL DELTA

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS (GlobeNewswire) - "Pasithea Therapeutics Corp...announced today that it has selected a lead therapeutic candidate for its PAS-003 program, a proprietary humanized monoclonal antibody (mAb) that targets α5β1 integrin....Scientists at Pasithea have performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS....Extensive mechanism of action studies link disease model efficacy to effects on the migration and adhesion of immune cells. The humanized lead candidate is a potent inhibitor of the primary ligand fibronectin (FN), has been optimized for high affinity and has high (sub-nanomolar) specificity with contact sites directly adjacent to the FN binding site documented by cryogenic electron microscopy (cryo-EM)."

Pipeline update • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function (GlobeNewswire) - "Pasithea Therapeutics Corp...today announced a publication in the internationally renowned scientific peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS), related to its PAS-003 drug discovery program, that describes an increased expression of α5/β1 (α5) integrin on motor neurons in ALS human and mouse tissue, as well as the blockade of this integrin as a potential new approach to treat ALS patients....Key findings from the publication show...the administration of a monoclonal antibody against α5 integrin increased survival in the SOD1G93A mouse model of ALS compared to an isotype control; and the administration of a monoclonal antibody against α5 integrin improved motor function on behavioral testing in the SOD1G93A mouse model of ALS compared to an isotype control."

Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders • Proteinopathy

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference (GlobeNewswire) - "Pasithea Therapeutics Corp...announced that Lawrence Steinman, Pasithea’s Chairman and a member of the National Academy of Sciences , will present preclinical data for PAS-003...on December 7th at the Antibody Engineering & Therapeutics Conference held in San Diego. Pasithea’s discovery candidate, PAS-003, has a novel mechanism of action with the potential to improve clinical outcomes in patients with ALS. The target, Alpha 5 Beta 1 integrin, and its potential role in ALS is supported by post-mortem human tissue studies and pre-clinical studies which show a reproducible significant improvement in behavior and survival in the SOD1 mouse model."

Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders